Figure 2.
Figure 2. Estimates of the probability of DFS, NRM, and relapse among all patients who received a therapeutic dose of 131I-BC8 antibody, followed by BU/CY.

Estimates of the probability of DFS, NRM, and relapse among all patients who received a therapeutic dose of 131I-BC8 antibody, followed by BU/CY.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal